Literature DB >> 33490040

Overview of Biologically Active Nucleoside Phosphonates.

Elisabetta Groaz1, Steven De Jonghe2.   

Abstract

The use of the phosphonate motif featuring a carbon-phosphorous bond as bioisosteric replacement of the labile P-O bond is widely recognized as an attractive structural concept in different areas of medicinal chemistry, since it addresses the very fundamental principles of enzymatic stability and minimized metabolic activation. This review discusses the most influential successes in drug design with special emphasis on nucleoside phosphonates and their prodrugs as antiviral and cancer treatment agents. A description of structurally related analogs able to interfere with the transmission of other infectious diseases caused by pathogens like bacteria and parasites will then follow. Finally, molecules acting as agonists/antagonists of P2X and P2Y receptors along with nucleotidase inhibitors will also be covered. This review aims to guide readers through the fundamentals of nucleoside phosphonate therapeutics in order to inspire the future design of molecules to target infections that are refractory to currently available therapeutic options.
Copyright © 2021 Groaz and De Jonghe.

Entities:  

Keywords:  antibacterials; anticancer drugs; antiparasitic agents; antivirals; nucleoside phosphonate; purinergic signaling

Year:  2021        PMID: 33490040      PMCID: PMC7821050          DOI: 10.3389/fchem.2020.616863

Source DB:  PubMed          Journal:  Front Chem        ISSN: 2296-2646            Impact factor:   5.221


  174 in total

1.  Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.

Authors:  Kyle E Giesler; Jose Marengo; Dennis C Liotta
Journal:  J Med Chem       Date:  2016-07-22       Impact factor: 7.446

2.  First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.

Authors:  Wendy Painter; Alice Robertson; Lawrence C Trost; Susan Godkin; Bernhard Lampert; George Painter
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Amidate Prodrugs of Cyclic 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine with Potent Anti-Herpesvirus Activity.

Authors:  Min Luo; Elisabetta Groaz; Steven De Jonghe; Robert Snoeck; Graciela Andrei; Piet Herdewijn
Journal:  ACS Med Chem Lett       Date:  2018-03-16       Impact factor: 4.345

4.  Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.

Authors:  Kyle E Giesler; Dennis C Liotta
Journal:  J Med Chem       Date:  2016-11-02       Impact factor: 7.446

5.  Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.

Authors:  Stephanie L Williams-Aziz; Caroll B Hartline; Emma A Harden; Shannon L Daily; Mark N Prichard; Nicole L Kushner; James R Beadle; W Brad Wan; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.

Authors:  William A Lee; Gong-Xin He; Eugene Eisenberg; Tomas Cihlar; Swami Swaminathan; Andrew Mulato; Kenneth C Cundy
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.

Authors:  Earl R Kern; Caroll Hartline; Emma Harden; Kathy Keith; Natalie Rodriguez; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.

Authors:  George R Painter; Merrick R Almond; Lawrence C Trost; Bernhard M Lampert; Johan Neyts; Erik De Clercq; Brent E Korba; Kathy A Aldern; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

9.  Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir.

Authors:  S Liekens; G Andrei; M Vandeputte; E De Clercq; J Neyts
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

10.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Marion G Peters; H w Hann Hw; Paul Martin; E Jenny Heathcote; P Buggisch; R Rubin; M Bourliere; K Kowdley; C Trepo; D f Gray Df; M Sullivan; K Kleber; R Ebrahimi; S Xiong; Carol L Brosgart
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

View more
  3 in total

1.  Fission Impossible: Stabilized miRNA-Based Analogs in Neurodegenerative Disease.

Authors:  Walter J Lukiw
Journal:  Front Neurosci       Date:  2022-05-03       Impact factor: 5.152

2.  Introduction of a cyano group at the 2-position of an (R,S)-3-hydroxy-2-(phosphonomethoxy)propyl (HPMP) derivative of thymine elicits selective anti-HBV activity.

Authors:  Shuai Tan; Elisabetta Groaz; Mark N Prichard; Raj Kalkeri; Roger Ptak; Piet Herdewijn
Journal:  RSC Med Chem       Date:  2021-04-29

3.  Acyclic nucleoside phosphonates with adenine nucleobase inhibit Trypanosoma brucei adenine phosphoribosyltransferase in vitro.

Authors:  Eva Doleželová; Tomáš Klejch; Petr Špaček; Martina Slapničková; Luke Guddat; Dana Hocková; Alena Zíková
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.